China healthcare weekly recap: GLP-1 R&D and capacity expansion become the main theme
AI summary card
China healthcare weekly recap: GLP-1 R&D and capacity expansion become the main theme
UBS reviews the weekly performance of China's healthcare sector, noting a pullback in A/H healthcare indices, while GLP-1 clinical data, Eli Lilly's supply chain investment in China, progress in innovative drugs, and catalysts for certain biotech names still constitute structural bright spots.
- HSHCI/HSBIO fell 2.9%/4.0%, respectively, from March 9 to 13, while Shenwan Healthcare A/H changed by -0.2%/-0.1%, ranking 13th/12th among A/H sectors.
- On the R&D side, Hansoh's HS20094 achieved up to 19.3% weight loss at 48 weeks, while Huadong Medicine's HDM1005 reduced HbA1c by 2.57% in phase 2 diabetes data.
- On the manufacturing side, Eli Lilly plans to invest US$3bn in China over the next 10 years to expand its supply chain, and to work with Pharmaron to build formulation capabilities related to the oral GLP-1 drug orforglipron.
- The H-share biologics sub-sector rose 4.1% for the week, boosted by news such as JacoBio's first-in-human panKRAS data, CARsgen's inclusion in Stock Connect, and earnings beats.
- UBS's top healthcare picks include BeOne, WuXi XDC, JD Health, and 3SBio, and the table lists multiple Buy-rated names along with their 2026 catalysts.
Report interpretation
Overview
This weekly report focuses on China's healthcare industry, with the latest developments of multiple GLP-1 drugs from R&D to manufacturing as the core theme. Although the A/H healthcare sector corrected overall during the week, the report believes that some innovative drugs, GLP-1, H-share biotech, and policy directions for medical devices still have structural catalysts.
Core views
UBS believes that sector performance diverged in the short term: A-share medical devices performed relatively best, while H-share biologics stood out driven by positive news. The GLP-1 segment benefits from both clinical data and supply chain investment catalysts. Data from Hansoh's and Huadong Medicine's related candidates strengthen domestic competitiveness in obesity and diabetes R&D, while Eli Lilly's large investment in China shows global pharma's emphasis on local manufacturing and supply chains.
Analysis framework
The report uses a combination of weekly event tracking, comparison of A/H healthcare indices and sub-sector performance, benchmarking of clinical data, tracking of drug approvals and IND progress, observation of financing and license-out trends, and individual stock catalyst lists to assess short-term sentiment and potential 2026 catalysts in China's healthcare sector.
Methodology notes
Assess relative sector strength through HSHCI, HSBIO, Shenwan Healthcare A/H, and sub-sector gains and losses.
The report presents index and sub-sector performance from March 9 to 13, distinguishing among A-share and H-share segments such as medical devices, biologics, TCM, distribution, chemical drugs, and services.
Evaluate candidate drug potential using weight-loss magnitude, HbA1c reduction, tolerability, and comparison with peer drugs.
The report compares HS20094's 48-week weight-loss data with tirzepatide SURMOUNT-CN data, and lists HbA1c changes for HDM1005 in diabetes patients.
Assess trends in China's drug manufacturing capability buildout through multinational pharma investment and partnerships in China.
The report focuses on Eli Lilly's plan to invest US$3bn in China over the next 10 years, cooperate with Pharmaron, and invest US$200m to build formulation capabilities.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- BeOne / ONC.OOne of UBS's top healthcare picks, listed as Buy in the table.
- Strengths
- Rapid net profit growth, attractive P/E valuation relative to Chinese pharma peers, and a strong global position in hematologic oncology.
- Weaknesses
- The report does not disclose detailed single-stock financial forecasts or target price.
- Comparison
- Valuation is more attractive relative to Chinese pharmaceutical peers.
- Risks
- Uncertainty around PoC for candidate solid tumor programs, commercialization delivery, and industry competition.
- WuXi XDC / 2268.HKOne of UBS's top healthcare picks, listed as Buy in the table.
- Strengths
- Benefits from demand for bioconjugate drug R&D and commercial manufacturing, with strong visibility on revenue and profit momentum.
- Weaknesses
- Business is sensitive to the health of external R&D and manufacturing demand.
- Comparison
- The report says its PEG multiple is attractive.
- Risks
- Changes in CMO demand, customer project progress, and industry competition.
- JD Health / 6618.HKOne of UBS's top healthcare picks, listed as Buy in the table.
- Strengths
- Rising online drug penetration and market share gains are expected to support strong revenue growth in 2026, while operating margins stabilize.
- Weaknesses
- The market still has doubts about the sustainability of growth momentum.
- Comparison
- UBS believes it may exceed company guidance and market expectations.
- Risks
- Competition in online pharmacies, pace of consumption recovery, and regulatory policy.
- 3SBio / 1530.HKOne of UBS's top healthcare picks, listed as Buy in the table.
- Strengths
- Attractive valuation, with potential BD milestone income and data readouts providing catalysts.
- Weaknesses
- The report does not provide a detailed valuation model.
- Comparison
- Listed as a preferred name within the pharma sector.
- Risks
- Uncertainty around BD revenue recognition, clinical data readouts, and innovative drug price negotiations.
- Eli Lilly / Pharmaron GLP-1 supply chainThe report mentions Eli Lilly's investment in China and cooperation with Pharmaron, making this a key event on the GLP-1 manufacturing side.
- Strengths
- Large long-term investment strengthens China's role in the oral GLP-1 manufacturing supply chain.
- Weaknesses
- Capacity buildout and ramp-up will take time.
- Comparison
- Together with domestic GLP-1 R&D progress, it forms an industry chain catalyst.
- Risks
- Risks related to capacity expansion progress, regulatory approval, global demand, and supply chain execution.
Key data
- Weekly performance of HSHCI/HSBIO-2.9%/-4.0%The period covered is March 9 to 13.
- Weekly performance of Shenwan Healthcare A/H-0.2%/-0.1%Ranked 13th/12th among A/H sectors, respectively.
- Weekly performance of A-share medical devices sub-sector+0.6%Best-performing A-share sub-sector; the report notes that BCI-theme companies outperformed.
- Weekly performance of H-share biologics sub-sector+4.1%Driven by positive news from JacoBio, CARsgen, and others.
- HS20094 weight-loss dataMaximum weight loss of 19.3% at 48 weeksHansoh's GLP-1/GIP candidate; the report says gastrointestinal tolerability was relatively good.
- HDM1005 HbA1c data3.0mg weekly dose reduced by 2.57%Phase 2 diabetes data for Huadong Medicine's GLP-1/GIP candidate; placebo was -0.57%.
- Eli Lilly's China investment planUS$3bn over the next 10 yearsTo expand the China supply chain and focus on manufacturing the oral GLP-1 drug orforglipron.
- Pharmaron cooperation investmentUS$200mTo establish and potentially scale up formulation capabilities.
- China biopharma financingUp 152% YoY in Jan-Feb 2026The chart title shows that China biopharma monthly funding increased YoY in Jan-Feb 2026.
- Global biopharma financingUp 133% YoY in Jan-Feb 2026The chart title shows that global biopharma monthly funding increased YoY in Jan-Feb 2026.
Impact & implications
The report suggests that China's healthcare sector remains constrained in the short term by pricing, competition, and policy uncertainty, but GLP-1, innovative drugs, outbound BD, medical device policy, and rising penetration of online pharmacies may still bring structural investment opportunities. For investors, the focus is not simply tracking sector indices, but selecting niche leaders with clinical data, commercialization delivery, manufacturing capability, attractive valuations, and 2026 catalysts.
Risks
- Price cuts in volume-based procurement or GPO projects exceeding expectations.
- Intensifying industry competition.
- Pricing after innovative drugs enter national reimbursement negotiations coming in below expectations.
- China's consumption recovery being slower than expected.
- Regulatory announcements and implementation being stricter than expected.
- Unexpected escalation of geopolitical tensions affecting company operations.
- Uncertainty in GLP-1 and innovative drug clinical data, approvals, and commercialization progress.
What to watch
- Follow-up clinical data, NDA/IND progress, and safety signals for GLP-1 candidates.
- The pace of capacity buildout for Eli Lilly's US$3bn investment in China and its cooperation with Pharmaron.
- Pipeline progress of innovative drugs from JacoBio, CARsgen, Junshi, Hengrui, Huadong Medicine, and others.
- The final version of pricing project guidelines for medical device diagnostic and treatment services and the strength of local implementation.
- Progress in BCI product registration and enterprise incubation driven by Jiangsu's brain-computer interface industry action plan.
- Trends in China's biopharma financing, IND counts, registered clinical trials, and license-out transactions in 2026.
- 2026 earnings delivery across sub-sectors such as online pharmacies, healthcare services, TCM, and vaccines.